Sarepta Therapeutics

Sarepta Therapeutics SRPT Stock

$14.53   -1.624920%
Add to favorites
Market Cap
$1.56B
LOW - HIGH [24H]
$14.53 - $14.95
VOLUME [24H]
$1.86M
P/E Ratio
726.50
Earnings per share
$0.02
ISIN
US8036071004
Price   Prediction

Sarepta Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Sarepta Therapeutics (SRPT) stock price today is 14.53 USD on Tech Market Large (-1.62% on the day). Updated .

Sarepta Therapeutics SRPT Financial and Trading Overview

Sarepta Therapeutics stock price 14.53 USD
Previous Close 15.13 USD
Open 15.11 USD
Bid 14.74 USD x 100
Ask 18.75 USD x 200
Day's Range 14.59 - 15.14 USD
52 Week Range 14.59 - 24.68 USD
Volume 2.39M USD
Avg. Volume 2.76M USD
Market Cap 1.58B USD
Beta (5Y Monthly) 0.454
PE Ratio (TTM) 738.50006
EPS (TTM) 0.02 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 21.77 USD

SRPT Valuation Measures

Enterprise Value 1.78B USD
Trailing P/E 738.50006
Forward P/E 9.957191
PEG Ratio (5 yr expected) -0.09
Price/Sales (ttm) 0.809611
Price/Book (mrq) 1.0359824
Enterprise Value/Revenue 0.912
Enterprise Value/EBITDA 75.103

Trading Information

Sarepta Therapeutics Stock Price History

Beta (5Y Monthly) 0.454
52-Week Change -9.88%
S&P500 52-Week Change 10.51%
52 Week High 24.68 USD
52 Week Low 14.59 USD
50-Day Moving Average 18.32 USD
200-Day Moving Average 18.46 USD

SRPT Share Statistics

Avg. Volume (3 month) 2.76M USD
Avg. Daily Volume (10-Days) 2.18M USD
Shares Outstanding 107.24M
Float 102.15M
Short Ratio 7.05
% Held by Insiders 4.81%
% Held by Institutions 99.24%
Shares Short 19.3M
Short % of Float 21.51%
Short % of Shares Outstanding 18.00%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:6

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -5.85%
Operating Margin (ttm) -0.42%
Gross Margin 23.40%
EBITDA Margin 1.21%

Management Effectiveness

Return on Assets (ttm) -0.15%
Return on Equity (ttm) -8.046%

Income Statement

Revenue (ttm) 1.96B USD
Revenue Per Share (ttm) 18.58 USD
Quarterly Revenue Growth (yoy) -4.50%
Gross Profit (ttm) 457.86M USD
EBITDA 23.76M USD
Net Income Avi to Common (ttm) -114618000 USD
Diluted EPS (ttm) 0.02
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 878.78M USD
Total Cash Per Share (mrq) 8.2 USD
Total Debt (mrq) 1.08B USD
Total Debt/Equity (mrq) 70.58 USD
Current Ratio (mrq) 3.463
Book Value Per Share (mrq) 14.257

Cash Flow Statement

Operating Cash Flow (ttm) 185.56M USD
Levered Free Cash Flow (ttm) 109.31M USD

Profile of Sarepta Therapeutics

Country United States
State MA
City Cambridge
Address 215 First Street
ZIP 02142
Phone 617 274 4000
Website https://www.sarepta.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 835

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Q&A For Sarepta Therapeutics Stock

What is a current SRPT stock price?

Sarepta Therapeutics SRPT stock price today per share is 14.53 USD.

How to purchase Sarepta Therapeutics stock?

You can buy SRPT shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Sarepta Therapeutics?

The stock symbol or ticker of Sarepta Therapeutics is SRPT.

Which industry does the Sarepta Therapeutics company belong to?

The Sarepta Therapeutics industry is Biotechnology.

How many shares does Sarepta Therapeutics have in circulation?

The max supply of Sarepta Therapeutics shares is 107.24M.

What is Sarepta Therapeutics Price to Earnings Ratio (PE Ratio)?

Sarepta Therapeutics PE Ratio is 726.50000000 now.

What was Sarepta Therapeutics earnings per share over the trailing 12 months (TTM)?

Sarepta Therapeutics EPS is 0.02 USD over the trailing 12 months.

Which sector does the Sarepta Therapeutics company belong to?

The Sarepta Therapeutics sector is Healthcare.

Sarepta Therapeutics SRPT included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
us US Tech Composite Total Return XCMP US 30190.38 USD —
+0.42
— — 29937.56 USD — 30324.94 USD — — — —
us US Tech Global Select Market Com NQGS US 12034.87 USD —
+0.42
— — 11933.12 USD — 12087.81 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7618.1 USD —
-0.66
— — 7605.28 USD — 7732.54 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2282.62 USD —
-0.95
— — 2279.7 USD — 2311.29 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3640.83 USD —
+0.48
— — 3611.7 USD — 3667.39 USD — — — —
us US Tech Next Generation 100 Inde NGX US 1696.58 USD —
+0.28
— — 1684.48 USD — 1709.46 USD — — — —
us US Tech Biotechnology NBI US 6971.7 USD —
-0.66
— — 6959.96 USD — 7076.43 USD — — — —
$2.2T
Total marketcap
$0
Total volume
BTC 58.15%   •   ETH 10.01%
Dominance
Select currency